Switch theme
Sign up to access all valuation multiples
Oriola Corp is a health and wellbeing company operating in Nordic countries. It offers services such as the distribution of pharmaceuticals and other health and well-being products, services, and dose dispensing. Oriola’s operations are divided into two segments which include distribution and wholesale.
2006
934
LTM Revenue $1.8B
LTM EBITDA $31.4M
$158M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oriola has a last 12-month revenue of $1.8B and a last 12-month EBITDA of $31.4M.
In the most recent fiscal year, Oriola achieved revenue of $1.8B and an EBITDA of -$0.8M.
Oriola expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oriola valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.6B | $1.8B | XXX | XXX | XXX |
| Gross Profit | $199M | $172M | XXX | XXX | XXX |
| Gross Margin | 12% | 10% | XXX | XXX | XXX |
| EBITDA | $24.8M | -$0.8M | XXX | XXX | XXX |
| EBITDA Margin | 2% | 0% | XXX | XXX | XXX |
| Net Profit | -$2.6M | -$22.2M | XXX | XXX | XXX |
| Net Margin | 0% | -1% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Oriola's stock price is EUR 1 (or $1).
Oriola has current market cap of EUR 185M (or $198M), and EV of EUR 147M (or $158M).
See Oriola trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $158M | $198M | XXX | XXX | XXX | XXX | $-0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Oriola has market cap of $198M and EV of $158M.
Oriola's trades at 0.1x LTM EV/Revenue multiple, and 5.0x LTM EBITDA.
Analysts estimate Oriola's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Oriola and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $158M | XXX | XXX | XXX |
| EV/Revenue | 0.1x | XXX | XXX | XXX |
| EV/EBITDA | -210.5x | XXX | XXX | XXX |
| P/E | -9.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 4.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOriola's NTM/LTM revenue growth is 5%
Oriola's revenue per employee for the last fiscal year averaged $1.9M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Oriola's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Oriola's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Oriola and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -103% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 5% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 9% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Alibaba Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oriola acquired XXX companies to date.
Last acquisition by Oriola was XXXXXXXX, XXXXX XXXXX XXXXXX . Oriola acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Oriola founded? | Oriola was founded in 2006. |
| Where is Oriola headquartered? | Oriola is headquartered in Finland. |
| How many employees does Oriola have? | As of today, Oriola has 934 employees. |
| Who is the CEO of Oriola? | Oriola's CEO is Ms. Katarina Gabrielson. |
| Is Oriola publicy listed? | Yes, Oriola is a public company listed on HEL. |
| What is the stock symbol of Oriola? | Oriola trades under OKDAV ticker. |
| When did Oriola go public? | Oriola went public in 2006. |
| Who are competitors of Oriola? | Similar companies to Oriola include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of Oriola? | Oriola's current market cap is $198M |
| What is the current revenue of Oriola? | Oriola's last 12-month revenue is $1.8B. |
| What is the current EBITDA of Oriola? | Oriola's last 12-month EBITDA is $31.4M. |
| What is the current EV/Revenue multiple of Oriola? | Current revenue multiple of Oriola is 0.1x. |
| What is the current EV/EBITDA multiple of Oriola? | Current EBITDA multiple of Oriola is 5.0x. |
| What is the current revenue growth of Oriola? | Oriola revenue growth between 2023 and 2024 was 12%. |
| Is Oriola profitable? | Yes, Oriola is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
